Acquisitions And Cost-Cutting 'Not Enough' To Boost Reckitt Benckiser: Analysis
Household and consumer health-care giant Reckitt Benckiser needs to focus less on acquisitions and cost-cutting if it wants to appease shareholders, according to a leading industry analyst.
Following the publication of the Nurofen parent's full-year results earlier today, Russ Mould, investment director at pension, investment and stockbroker firm AJ Bell, said, "A return to sales growth in the fourth quarter, increased cost-saving targets and a higher dividend are not proving enough for shareholders in Reckitt Benckiser, whose shares are the worst performers in the FTSE 100 in early trading."
Reckitt Benckiser posted flat like-for-like revenue (at constant-currency levels) for full-year 2017 (£11.5 billion), with an increase of 2% reported in the final quarter of the year (£3.29 billion).
Try European Supermarket Magazine PREMIUM – 30 Day FREE Trial.
A trial subscription gives unrestricted access to all premium site content, app content, weekly email content and European Supermarket Magazine digital edition for a full 30 days. Try it now!